| Literature DB >> 35069488 |
Sergio George1, Ximena Aguilera2, Pablo Gallardo3, Mauricio Farfán3, Yalda Lucero1,4, Juan Pablo Torres1,3, Roberto Vidal5,6,7, Miguel O'Ryan1,6.
Abstract
Gut microbiota composition during the first years of life is variable, dynamic and influenced by both prenatal and postnatal factors, such as maternal antibiotics administered during labor, delivery mode, maternal diet, breastfeeding, and/or antibiotic consumption during infancy. Furthermore, the microbiota displays bidirectional interactions with infectious agents, either through direct microbiota-microorganism interactions or indirectly through various stimuli of the host immune system. Here we review these interactions during childhood until 5 years of life, focusing on bacterial microbiota, the most common gastrointestinal and respiratory infections and two well characterized gastrointestinal diseases related to dysbiosis (necrotizing enterocolitis and Clostridioides difficile infection). To date, most peer-reviewed studies on the bacterial microbiota in childhood have been cross-sectional and have reported patterns of gut dysbiosis during infections as compared to healthy controls; prospective studies suggest that most children progressively return to a "healthy microbiota status" following infection. Animal models and/or studies focusing on specific preventive and therapeutic interventions, such as probiotic administration and fecal transplantation, support the role of the bacterial gut microbiota in modulating both enteric and respiratory infections. A more in depth understanding of the mechanisms involved in the establishment and maintenance of the early bacterial microbiota, focusing on specific components of the microbiota-immunity-infectious agent axis is necessary in order to better define potential preventive or therapeutic tools against significant infections in children.Entities:
Keywords: Clostridioides difficile; RSV; childhood infections; diarrheagenic Escherichia coli (DEC); gut microbiota; necrotizing enterocolitis; norovirus; rotavirus
Year: 2022 PMID: 35069488 PMCID: PMC8767011 DOI: 10.3389/fmicb.2021.793050
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Definition of relevant terms included in microbiota studies, and acronyms used in this review.
| Term | Definition | References |
| Relative abundance | Quantitative measure of the number of organisms, operational taxonomic units (OTUs), operational phylogenetic units (OPUs), amplicon sequence variants (ASVs) or sequences detected in a sample in relation to all others in that sample (e.g., If there are 100 organisms in a sample, and 20 are identified as | |
| Richness | Number of unique organisms detected in a specific sample. | |
| Diversity | Estimate incorporating species richness and abundance to measure the microbial variability either within (α) or between (β) samples. |
|
| Enterotype | Classification of organisms into |
|
| Healthy microbiota and dysbiosis | A healthy microbiota can be described in terms of ecological stability (i.e., the ability to resist community structure change under stress or to rapidly return to baseline following a stress-related change) and by an idealized (presumably health-associated) composition or a desirable functional profile. Dysbiosis can be defined as an alteration in the microbiome from the normal or healthy state. For the purpose of this review, as microbiota composition is dependent on multiple variables, a healthy microbiota is considered to be the group cataloged as “healthy controls” in each study discussed. | |
|
| ||
|
|
| |
|
| ||
| ALRI | Acute lower respiratory infection | |
| AMP | Antimicrobial peptides | |
| AMR | Antimicrobial resistance | |
| ARI | Acute respiratory infection | |
| AURI | Acute upper respiratory infection | |
| BGM | Bacterial gut microbiota | |
| CD |
| |
| DEC | Diarrheagenic | |
| EAEC | Enteroaggregative | |
| EHEC | Enterohemorrhagic | |
| EIEC | Enteroinvasive | |
| EPEC | Enteropathogenic | |
| ETEC | Enterotoxigenic | |
| GF mice | Germ free mice | |
| GM | Gut microbiota | |
| IFN | Interferon | |
| LPS | Lipopolysaccharide | |
| MAMP | Microbiota- associated molecular patterns | |
| NEC | Necrotizing enterocolitis | |
| NV | Norovirus | |
| OPU | Operational phylogenetic unit | |
| OTU | Operational taxonomic unit (OTUs) | |
| PAMP | Pathogens-associated molecular patterns | |
| PRR | Pattern recognition receptor | |
| RSV | Respiratory syncytial virus | |
| RV | Rotavirus | |
| SCFA | Short chain fatty acids | |
| SFB | Segmented filamentous bacteria | |
| STEC | Shiga toxin-producer | |
| TLR/NLR | Toll-like receptor/NOD-like receptor | |
Mechanisms involving direct interaction between the gut microbiota and pathogens.
| Mechanism | Description | References |
| Availability of host sugars | − Pathogens, such as | |
| − Enterohemorrhagic | ||
| Gut microbiota- mediated glycan modification | − Soluble factors produced by |
|
| Direct binding of gut microbiota bacteria and viral pathogens | − Norovirus (NV) binds to HBGA-like carbohydrates expressed on the surface of the gut bacteria | |
| − Rotavirus (RV) infectivity is reduced by segmented filamentous bacteria in | ||
| Direct effect of microbiota- derived metabolites on pathogens | − Exposure of | |
| − Bacteriocins produced by the microbiota act directly on pathogens by limiting infection (e.g., Nisin produced by | ||
| − Other gut microbiota metabolites (such as microbial amino acids, vitamins, and quorum sensing autoinducers) act on pathogens by limiting or promoting infection. |
Recognized interactions between the immune system and the gut microbiota.
| Immune system component | Function | Interactions with the microbiota | References |
|
| |||
| Mucus | Physical barrier | − Germ-free (GF) mice display alterations in the composition and structure of the mucus layer compared to normally-colonized mice. | |
| − Bacterial factors (LPS, peptidoglycan) promote mucus secretion and restoration in GF mice. | |||
| − Host glycosylation patterns influence the composition of mucus-associated bacteria. | |||
| − “Mucolytic bacteria” use mucins as nutrients. | |||
| Tight junctions | Restrict paracellular permeability to pathogens | Gut microbiota perturbation induced by a high fat diet and antibiotic use is associated with reduced expression of tight junction proteins in mice, and increased intestinal permeability. | |
| Pattern recognition receptors (PRR) | Innate immune-system receptors recognizing pathogens or microbiota- associated molecular patterns (PAMPs-MAMPs) activating immune responses or maintaining gut homeostasis. | − There are bidirectional interactions between the microbiota PAMPs and PRRs. | |
| − Microbiota recognition by PRRs is essential in immune system development [e.g., antimicrobial peptide (AMP) production, epithelial proliferation and gut-associated lymphoid tissue development]. | |||
| − PRR interactions with the microbiota maintain microbiota homeostasis (e.g., NOD1-defficient mice display an increase in | |||
| − Altered PRR detection in the gut microbiota is associated with increased intestinal inflammation in response to pathogens, and may lead to chronic inflammation-associated diseases, such as cancer and metabolic syndromes. | |||
| − In vaginally delivered newborn mice, downregulation of Toll-like receptors (TLR) signaling in intestinal epithelial cells is critical in stablishing gut tolerance to bacteria during this period, which allows the gut colonization. | |||
| Antimicrobial peptides (AMP) | Limit pathogen interaction with the epithelia | − BGM (e.g., | |
| − SCFA (mainly butyrate, acetate, and propionate) are metabolites produced by certain gut-microbiota components from metabolism of dietary fiber. SCFAs produced by the microbiota induce intestinal epithelial cell production of AMPs. | |||
| − AMPs regulate the quantity and composition of intestinal microbiota. | |||
|
| |||
|
| |||
|
| |||
| IgA- B cell response | Secretory immunoglobulin | − Enteric microbiota induce mucosal immune system maturation and production of high levels of secretory IgA. |
|
| − In pIgR-deficient mice (deficient in all secretory Igs): presence of secretory IgA affects microbial fitness and thereby microbiota composition. | |||
| IgE - B cell response | Immunoglobulin E, related to Th2 and allergic response. | − Germ-free mice have an elevated systemic IgE response, driven by a B-cell isotype change in mucosal lymphoid tissues, in a LTCD4 and IL-4-dependant manner. |
|
| − Colonization of GF mice during the first 2 weeks of life (but not after) restores IgE levels permanently until adulthood. This is dependent on a high BGM diversity. | |||
| Regulatory T cell (TReg) response | Maintains immune balance by limiting effector immune cell responses. In infections, they can have either a potentially protective role, by limiting pathogen-induced immunopathology, or detrimental by limiting effector cell-mediated eradication of pathogen. | − Microbiota can induce differentiation of naïve-T cells to peripheral TReg cells, mediated by SCFA production from dietary fiber metabolism (e.g., by Clostridia clusters XIVa, IV, and XVIII), or by bacterial polysaccharides (e.g., from | |
| Th17 cell response | Potentially protective mainly against bacterial and fungal, extracellular infections. | − Segmented filamentous bacteria (and their flagellin) from gut microbiota induce Th17 cell differentiation. | |
| Invariant natural killer T cells (iNKT) | Subset of T lymphocytes, harboring T-cell receptors (TCR) recognizing glycosphingolipid presented by CD1d. iNKT activation can produce either a Th1 or Th2 cytokine response. | − GF mice have diminished and hyporesponsive iNKT in peripheral tissues, but augmented colonic iNKT associated with colitis. | |
| − Colonization with complete BGM, | |||
| − Several commensal bacteria have sphingolipids that activate iNKT, including | |||
Abundance of the gut microbiota’s main phyla and their components during diarrhea episodes compared to healthy controls.
| Description | References | |
| Proteobacteria abundance | − Higher relative abundance of the phylum Proteobacteria and/or its subtaxas (mainly | |
| − Infants with viral diarrhea (RV or NV) had lower relative abundance of Proteobacteria compared to healthy children in one study. |
| |
| − |
| |
| Firmicutes abundance | Higher abundance in healthy controls compared to children with diarrhea, especially those specific components considered markers of a healthy gut microbiota: | |
| − Bacterial genera of the | ||
| − A |
| |
| Bacteroides abundance | − Bacteroidota were increased in diarrheal samples of children irrespective of their etiology, and in children with diarrhea caused by diarrheagenic | |
| − The genus | ||
| − The genus |
| |
| − The genus |
Differences in the gut microbiota composition during childhood infectious diarrhea according to etiology.
| Description | References | |
| Bacterial v/s viral diarrheas | In children from Bangladesh, the abundance of |
|
| In children from Vietnam with diarrhea, when cluster analysis based on β -diversity data was performed, samples were segregated into 4 community-structure types (or Enterotypes). The |
| |
| In children from Chile, DEC infection was associated with a higher proportion of Proteobacteria and a lower proportion of Firmicutes at the phylum level, a greater abundance of |
| |
| Viral v/s virus-bacteria co-infection | In children from Qatar with RV or NV-diarrhea, co-infection with bacteria was associated with differences in microbiota composition: RV co-infection with EAEC was associated with a predominance of |
|
| Different viral pathogens | In children from Chile with viral diarrhea, microbiota composition of samples with different enteric viruses clustered together. |
|
| In children from Taiwan with viral diarrhea, children with RV infection had a significantly lower α-diversity score compared to children with NV, and the latter was no different from controls. |
| |
| In children from China with viral diarrhea, the RV group had lower α-diversity (Simpson index) than the NV group. The RV group exhibited higher abundances of Actinobacteria and Verrucomicrobia at the phylum level, and higher abundances of |
| |
| Different bacterial pathogens | In a group of adults and children with bacterial infections ( |
FIGURE 1α-diversity and relative abundance of main taxa in children with acute diarrhea compared to healthy controls. Red represents higher diversity or abundance in children with diarrhea, and blue represents higher values in healthy controls.
Key factors involved in the modulation of lung immunity through the Gut-Lung axis.
| Gut microbiota component | Description | Interaction with respiratory tract immunity | Effect on lung immunity | References |
| SCFA | Metabolites derived from gut microbiota fermentation of undigested dietary fibers. Propionate, acetate, and butyrate are the main SCFA. | − SCFA translocate from gut to the systemic circulation and reach the bone marrow, where they promote hematopoiesis and differentiation of different lineages depending on context (e.g., during influenza infection they induce monocytes and dendritic cell progenitors differentiation and increase of patrolling macrophages which reach the lung). | ↑ or ↓ | |
| − Acetate promotes a type I-IFN response in pulmonary epithelial cells, in a Gpr43 receptor-dependent manner. | ||||
| − During influenza infection, SCFAs have a direct effect on LTCD8 activation by enhancing cellular metabolism in a GPR41 (G protein coupled receptor) dependent manner. | ||||
| − SCFAs promote an extrathymic peripheral Treg cell pool, associated with decreased allergic airway diseases through histone deacetylase inhibition. | ||||
| Segmented filamentous bacteria (SFB) | Commensal gut microbiota belonging to the Firmicutes phylum; colonization in humans occurs during the first 2 years of life, with an important decrease after 36 months. | − SFBs promote differentiation of TCD4 to Th17 in a IL1R-dependent manner during pulmonary fungal infections in mice. | ↑ | |
| − Th17 response induced by SFB is involved in lung autoimmune disease in mice. | ||||
| Desaminotyrosine | Degradation product of flavonoids, plant-derived polyphenol compounds with intestinal and systemic anti-inflammatory effects. | − Desaminotyrosine produced by | ↑ | |
| PRR agonists | Activation of PRR, including Toll-like receptors (TLR) and Nod-like receptor (NLR) by gut-bacterial ligands enhance antiviral respiratory immune responses. | −Gut TLR4 activation by LPS induces protection against | ↑ | |
| − Gut (NLR) activation by their ligands determines an effective lung immunity to | ||||
| − Rectal inoculation of TLR agonists CpG (TLR9 agonist), Poly I:C (TLR3 agonist), peptidoglycan (TLR2 agonist), and LPS (TLR-4 agonist) restore immunity to influenza virus in antibiotic-treated Mice. TLR-5 activation by Flagellin is necessary for antibody responses against influenza virus vaccination in mice. |
FIGURE 2Bidirectional interactions between the gut microbiota and gastrointestinal or respiratory tract infections in childhood.